By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 4 November 2026
GLP-1-based weight-loss injections have changed medical weight management. But there are big differences between Ozempic, Wegovy, Mounjaro and Saxenda – in active ingredient, application, trial efficacy and price. This overview sorts the options for you.
Important up front: none of these injections is a lifestyle product. All of them are prescription-only and intended only for a medical indication – typically obesity or overweight with a weight-related condition.
| Injection | Ingredient | Use | EU approval | Trial efficacy | Costs/month (approx.) |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | 1× weekly | Type 2 diabetes (2018) | Not approved for weight loss; off-label possible | 300–450 € |
| Wegovy | Semaglutide | 1× weekly | Weight management (2022) | ~15 % weight loss (68 weeks) | 330–480 € |
| Mounjaro | Tirzepatide | 1× weekly | Diabetes (2022) + weight management (2023) | ~20 % weight loss (72 weeks) | 350–450 € |
| Saxenda | Liraglutide | 1× daily | Weight management (2015) | ~8 % weight loss (56 weeks) | 330–400 € |
Efficacy figures come from the pivotal trials (STEP 1, SURMOUNT-1, SCALE); costs are guide values for self-payers and vary by dose and pharmacy.
A rough orientation – the final choice is always made together with the medical team:
All GLP-1 injections share a similar side-effect profile: nausea, digestive complaints and fullness are especially frequent at the start. Rarer but serious risks include gallstones and inflammation of the pancreas. Contraindications and interactions are checked by the medical team before every prescription.
Apart from the diabetes indications, statutory insurers usually do not pay. Some insurers reimburse in exceptional cases with a clear medical necessity – an individual application process is worth trying. Details on individual prices are on the linked product pages.
According to the trial data, tirzepatide (Mounjaro) with about 20 % weight loss, followed by semaglutide (Wegovy) at about 15 % and liraglutide (Saxenda) at about 8 %. Efficacy alone does not determine the right choice, though.
As a rule, no. The prerequisite is a medically established indication – BMI ≥ 30 or BMI ≥ 27 with a weight-related condition. Purely cosmetic wishes are not a medical indication.
Partially, for the diabetes indication. For pure weight management, statutory insurers usually do not pay; exceptions are possible via applications.
The trials cover usage periods of one to two years. Long-term use happens under medical supervision with regular check-ups.